NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $14.84 +0.30 (+2.06%) Closing price 10/27/2026 04:00 PM EasternExtended Trading$14.50 -0.34 (-2.29%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$14.28▼$14.9850-Day Range$12.93▼$22.9552-Week Range$6.73▼$23.19Volume488,060 shsAverage VolumeN/AMarket Capitalization$955.03 millionP/E RatioN/ADividend YieldN/APrice Target$33.71Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors. Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers. The company continues to advance these and other candidates through clinical development. The company was formerly known as Cullinan Oncology and adopted the Cullinan Therapeutics name in 2024. Cullinan operates as a biotechnology company with research and clinical-development activities in the United States and collaborates with external partners to develop and advance potential cancer treatments. Nadim Ahmed serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCGEM MarketRank™: 3.489358836205 of 5 starsCullinan Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 273rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $33.71, representing about 127.2% upside from its current price of $14.84.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.06) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.99% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 8.21.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 0.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentCullinan Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cullinan Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $780,360.00 in company stock.Percentage Held by Insiders8.60% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDAOctober 27 at 7:00 AM | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG ResearchOctober 21, 2026 | americanbankingnews.comWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7. | Porter & Company (Ad)Cullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer TrialOctober 19, 2026 | finance.yahoo.comCullinan Moves CLN-049 Into Phase 2 Development For Relapsed/Refractory AMLOctober 8, 2026 | rttnews.comCullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid LeukemiaOctober 8, 2026 | finance.yahoo.comCullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaOctober 8, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)October 3, 2026 | theglobeandmail.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.35 at the beginning of 2026. Since then, CGEM stock has increased by 43.4% and is now trading at $14.84. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.01. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $232 million in an IPO on Friday, January 8th 2021. The company issued 11,900,000 shares at $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' top institutional investors include Ellsworth Advisors LLC (0.12%) and GAMMA Investing LLC. Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Corrine Savill, Jeffrey Alan Jones, Jennifer Michaelson, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Allogene Therapeutics (ALLO), Intellia Therapeutics (NTLA), Palantir Technologies (PLTR), Solid Biosciences (SLDB), Iovance Biotherapeutics (IOVA), Kura Oncology (KURA) and IonQ (IONQ). Company Calendar Last Earnings8/06/2026Today10/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, CGEM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinantherapeutics.com Phone617-410-4650FaxN/AEmployees109Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$33.71 High Price Target$42.00 Low Price Target$26.00 Potential Upside/Downside+127.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares64,355,000Free Float58,820,000Market Cap$955.03 million OptionableOptionable Beta-0.05 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CGEM) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYesterday's deadline changed everythingIn June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
